Multicenter comprehensive methodological and technical analysis of 832 pressurized intraperitoneal aerosol chemotherapy (PIPAC) interventions performed in 349 patients for peritoneal carcinomatosis treatment: An international survey study.

Détails

ID Serval
serval:BIB_23BAA90FE322
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Titre
Multicenter comprehensive methodological and technical analysis of 832 pressurized intraperitoneal aerosol chemotherapy (PIPAC) interventions performed in 349 patients for peritoneal carcinomatosis treatment: An international survey study.
Périodique
European journal of surgical oncology
Auteur(s)
Nowacki M., Alyami M., Villeneuve L., Mercier F., Hubner M., Willaert W., Ceelen W., Reymond M., Pezet D., Arvieux C., Khomyakov V., Lay L., Gianni S., Zegarski W., Bakrin N., Glehen O.
ISSN
1532-2157 (Electronic)
ISSN-L
0748-7983
Statut éditorial
Publié
Date de publication
07/2018
Peer-reviewed
Oui
Volume
44
Numéro
7
Pages
991-996
Langue
anglais
Notes
Publication types: Journal Article ; Multicenter Study
Publication Status: ppublish
Résumé
Pressurized intraperitoneal aerosol chemotherapy (PIPAC) is a new drug delivery method offered in selected patients suffering from non-resectable peritoneal carcinomatosis (PC). As reported experience is still limited, we conducted a survey among active PIPAC centers aiming to report their technical approach and clinical findings.
An online survey was sent to active PIPAC centers worldwide. The questionnaire consisted of 34 closed questions and was conducted over a period of 3 months beginning in March 2017.
Nine out of 15 contacted centers completed the questionnaire totaling 832 PIPAC procedures in 349 patients. Most common indications for PIPAC were PC from gastric, ovarian and colorectal origin. The mean time between each PIPAC procedure was 6-8 weeks. Seven of nine (77.8%) centers evaluate the PCI at every PIPAC procedure. At least four tissue samples for histopathology analysis were retrieved in 5 (55.6%). All centers (100%) use the same chemotherapy protocol: oxaliplatin at a dosage of 92mg/m <sup>2</sup> for PC of colorectal origin and a combination of cisplatin and doxorubicin at a dosage of 7.5mg/m <sup>2</sup> and 1.5mg/m <sup>2</sup> , respectively, for other types of PC. Eight centers (88.9%) perform routine radiological evaluation before first PIPAC and after third PIPAC.
These data confirm that PIPAC procedures are homogeneously performed in established centers. Standardization of the procedure will facilitate future international multicenter prospective clinical trials.
Mots-clé
Administration, Inhalation, Antineoplastic Agents/administration & dosage, Antineoplastic Combined Chemotherapy Protocols/administration & dosage, Appendiceal Neoplasms/drug therapy, Appendiceal Neoplasms/pathology, Carcinoma/drug therapy, Carcinoma/secondary, Cisplatin/administration & dosage, Colorectal Neoplasms/drug therapy, Colorectal Neoplasms/pathology, Doxorubicin/administration & dosage, Female, Gastrointestinal Neoplasms/drug therapy, Gastrointestinal Neoplasms/pathology, Humans, Injections, Intraperitoneal/methods, Male, Mesothelioma/drug therapy, Mitomycin/administration & dosage, Organoplatinum Compounds/administration & dosage, Ovarian Neoplasms/drug therapy, Ovarian Neoplasms/pathology, Peritoneal Neoplasms/drug therapy, Peritoneal Neoplasms/secondary, Practice Patterns, Physicians', Stomach Neoplasms/drug therapy, Stomach Neoplasms/pathology, Surveys and Questionnaires, Innovation, Multicenter study, PIPAC, Peritoneal carcinomatosis, Practice survey, Safety procedure
Pubmed
Web of science
Création de la notice
15/03/2018 19:45
Dernière modification de la notice
05/08/2018 16:01
Données d'usage